Quantcast

Industry news that matters to you.  Learn more

Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform

Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications.  Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions.  ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.